{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["36(1)"],"submitter":["Ricciardelli G"],"pubmed_abstract":["Objectives
To analyze the effect of the employment of polyvinylpyrrolidone-iodine (PVP-I) 0.6% eye drop on the clinical course of patients affected by Adenoviral Keratoconjunctivitis (AKC).Methods
Consecutive patients with clinical signs of AKC and positive results of AdenoPlus test were enrolled from four Italian Centres. Patients were randomized to receive: PVP-I 0.6% eye drops four times/daily for 20 days (Group A) or hyaluronate-based tear substitutes four times/daily for 20 days (Group B). Best-corrected visual acuity (BCVA), optical coherence tomography (OCT) Optovue iVue pachymetry map; corneal haze; conjunctival injection and chemosis; subepithelial corneal infiltrates (SEIs); corneal and conjunctival staining and corneal densitometry were recorded at diagnosis and "],"journal":["Eye (London, England)"],"pagination":["160-166"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8727611"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy and tolerability of polyvinylpyrrolidone-iodine 0.6% treatment in adenoviral keratoconjunctivitis: a Prospective Randomized Controlled Study."],"pmcid":["PMC8727611"],"pubmed_authors":["Ricciardelli G","Giannaccare G","Allegrini D","Cennamo M","Antonini M","Bernabei F","Morelli A","Scorcia V","Mencucci R","Coassin M","Di Zazzo A","Romano MR"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy and tolerability of polyvinylpyrrolidone-iodine 0.6% treatment in adenoviral keratoconjunctivitis: a Prospective Randomized Controlled Study.","description":"Objectives
To analyze the effect of the employment of polyvinylpyrrolidone-iodine (PVP-I) 0.6% eye drop on the clinical course of patients affected by Adenoviral Keratoconjunctivitis (AKC).Methods
Consecutive patients with clinical signs of AKC and positive results of AdenoPlus test were enrolled from four Italian Centres. Patients were randomized to receive: PVP-I 0.6% eye drops four times/daily for 20 days (Group A) or hyaluronate-based tear substitutes four times/daily for 20 days (Group B). Best-corrected visual acuity (BCVA), optical coherence tomography (OCT) Optovue iVue pachymetry map; corneal haze; conjunctival injection and chemosis; subepithelial corneal infiltrates (SEIs); corneal and conjunctival staining and corneal densitometry were recorded at diagnosis and ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-22T10:08:48.318Z","creation":"2025-04-05T23:29:35.693Z"},"accession":"S-EPMC8727611","cross_references":{"pubmed":["33654316"],"doi":["10.1038/s41433-020-01344-6"]}}